⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 25, 2023Clinical Journal of the American Society of NephrologyOpen Access

Pharmacokinetic Properties of Dapagliflozin in Hemodialysis and Peritoneal Dialysis Patients

View Full Paper

Ask AI

Bookmark

Share

Abstract

Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients (DARE-ESKD 1), NCT05343078.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Barreto et al. (2023) studied this question.

synapsesocial.com/papers/69dd3e4eac7bdbc6c7101119 https://doi.org/10.2215/cjn.0000000000000196

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney DiseaseClinical Guideline · 2022 · 1,342 citations
2Biology of Human Sodium Glucose TransportersReview · 2011 · 1,426 citations
3Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Human Clinical Trial · 2020 · 240 citations
42. Classification and Diagnosis of Diabetes:<i>Standards of Medical Care in Diabetes—2020</i>Original Research · 2019 · 3,295 citations
5Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitusRCT · 2011 · 115 citations